{"entity":{"id":"nct06260774","kind":"trial","name":"Study of TTX-MC138 in Subjects With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of TTX-MC138 in advanced solid tumours, run by TransCode Therapeutics, active and no longer recruiting.","summary":"Study of TTX-MC138 in Subjects With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06260774 by TransCode Therapeutics, with 16 participants enrolled, started 2024-09-05 and due to reach its primary completion in 2025-09-30. Interventions recorded: TTX-MC138.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06260774","url":"https://clinicaltrials.gov/study/NCT06260774"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06260774","phase":"1/2","setting":"A Phase 1/2 Multicenter, Open-Label, Dose-escalation and Expansion Study of TTX-MC138 in Subjects With Advanced Solid Tumors","sponsor":"TransCode Therapeutics","participation":[{"nct":"NCT06260774","source":"https://clinicaltrials.gov/study/NCT06260774","fetchedAt":"2026-10-07T16:54:29.928Z","studySha256":"b49bd728516ebde957178fcba5e5b819245c6dbacd24eb42175c7ebadc5d86d3","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2025-10-02","leadSponsor":"TransCode Therapeutics","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"80 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":16,"enrolmentType":"ACTUAL","siteCount":4,"recruitingSiteCount":0,"countries":["United States"]}],"started":"2024-09-05","startedType":"actual","enrolled":16,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06260774/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}